Journal of mucopolysaccharidosis and rare diseases

Association for Research of MPS and Rare Diseases (뮤코다당증연구학회)
권호 표지
DOI QR코드

DOI QR Code

Newborn Screening for Lysosomal Storage Diseases in Taiwan

  • Received : 2017.05.25
  • Accepted : 2017.06.14
  • Published : 2017.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Lysosomal storage diseases (LSDs) are a group of rare inherited metabolic disorders caused by the deficiency of specific lysosomal enzymes and subsequent accumulation of substrates. Enzyme deficiency leads to progressive intra-lysosomal accumulation of the incompletely degraded substances, which cause dysfunction and destruction of the cell and eventually multiple organ damage. Patients have a broad spectrum of clinical phenotypes which are generally not specific for some LSDs, leading to missed or delayed diagnosis. Due to the availability of treatment including enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation for some LSDs, early diagnosis is important. ERT products have been approved with optimal outcomes for some LSDs in the recent decades, including Gaucher, Fabry, mucopolysaccharidosis (MPS) I, Pompe, MPS VI, MPS II, and MPS IVA diseases. ERT can stabilize the clinical condition, prevent disease progression, and improve the long-term outcome of these diseases, especially if started prior to irreversible organ damage. Based on the availability of therapy and suitable screening methods in the recent years, some LSDs, including Pompe, Fabry, Gaucher, MPS I, MPS II, and MPS VI diseases have been incorporated into nationwide newborn screening panels in Taiwan.

Keywords

References

  1. Schielen PCJI, Kemper EA, Gelb MH. Newborn screening for lysosomal storage diseases: a concise review of the literature on screening methods, therapeutic possibilities and regional programs. Int J Neonat Screen 2017;3:6. https://doi.org/10.3390/ijns3020006
  2. Kingma SD, Bodamer OA, Wijburg FA. Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening. Best Pract Res Clin Endocrinol Metab 2015;29:145-57. https://doi.org/10.1016/j.beem.2014.08.004
  3. Nakamura K, Hattori K, Endo F. Newborn screening for lysosomal storage disorders. Am J Med Genet C Semin Med Genet 2011;157C:63-71.
  4. The official website of the Chinese Foundation of Health, Taipei, Taiwan [cited 2017 May 1]. Available from: https://www.cfoh.org.tw/about.html.
  5. Hirschhorn R, Reuser A. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001:3389-420.
  6. Chien YH, Hwu WL, Lee NC. Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol 2013;54:219-27. https://doi.org/10.1016/j.pedneo.2013.03.009
  7. Yang CF, Yang CC, Liao HC, Huang LY, Chiang CC, Ho HC, et al. Very early treatment for infantile-onset Pompe disease contributes to better outcomes. J Pediatr 2016;169:174-80. https://doi.org/10.1016/j.jpeds.2015.10.078
  8. Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC, et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 2008;122:e39-45. https://doi.org/10.1542/peds.2007-2222
  9. Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 2009;124:e1116-25. https://doi.org/10.1542/peds.2008-3667
  10. Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL. Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr 2011;158:1023-7. https://doi.org/10.1016/j.jpeds.2010.11.053
  11. Chiang SC, Hwu WL, Lee NC, Hsu LW, Chien YH. Algorithm for Pompe disease newborn screening: results from the Taiwan screening program. Mol Genet Metab 2012;106:281-6. https://doi.org/10.1016/j.ymgme.2012.04.013
  12. Yang CF, Liu HC, Hsu TR, Tsai FC, Chiang SF, Chiang CC, et al. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. Am J Med Genet A 2014;164A:54-61.
  13. Chien YH, Lee NC, Chen CA, Tsai FJ, Tsai WH, Shieh JY, et al. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. J Pediatr 2015;166:985-91.e1-2. https://doi.org/10.1016/j.jpeds.2014.10.068
  14. Desnick RJ, Ioannou YA, Eng CM. a-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. 8th edition. New York, NY: McGraw-Hill, 2001:3733-74.
  15. Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2009;2:450-6. https://doi.org/10.1161/CIRCGENETICS.109.862920
  16. Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 2009;30:1397-405. https://doi.org/10.1002/humu.21074
  17. Hsu TR, Hung SC, Chang FP, Yu WC, Sung SH, Hsu CL, et al. Later onset fabry disease, cardiac damage progress in silence: Experience with a highly prevalent mutation. J Am Coll Cardiol 2016;68:2554-63. https://doi.org/10.1016/j.jacc.2016.09.943
  18. Lin HY, Liu HC, Huang YH, Liao HC, Hsu TR, Shen CI, et al. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa. J Chin Med Assoc 2014;77:190-7. https://doi.org/10.1016/j.jcma.2013.11.006
  19. Lin HY, Liu HC, Huang YH, Liao HC, Hsu TR, Shen CI, et al. Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A). BMJ Open 2013;3(7):e003146. https://doi.org/10.1136/bmjopen-2013-003146
  20. Neufeld EF, Muenzer J. The mucoplysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, assoc, editors. The Metabolic and Molecular Bases of Inherited Disease, 8th edition. New York: McGraw-Hill, 2001:3421-52.
  21. Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A 2009;149A:960-4. https://doi.org/10.1002/ajmg.a.32781
  22. Lin SP, Lin HY, Wang TJ, Chang CY, Lin CH, Huang SF, et al. A pilot newborn screening program for mucopolysaccharidosis type I in Taiwan. Orphanet J Rare Dis 2013;8:147. https://doi.org/10.1186/1750-1172-8-147
  23. Chuang CK, Lin HY, Wang TJ, Tsai CC, Liu HL, Lin SP. A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Orphanet J Rare Dis 2014;9:135. https://doi.org/10.1186/s13023-014-0135-3
  24. Chuang CK, Lin SP, Chung SF. Diagnostic screening for mucopolysaccharidoses by the dimethylmethylene blue method and two dimensional electrophoresis. Zhonghua Yi Xue Za Zhi (Taipei) 2001;64:15-22.
  25. Lin SP, Chang JH, Lee-Chen GJ, Lin DS, Lin HY, Chuang CK. Detection of Hunter syndrome (mucopolysaccharidosis type II) in Taiwanese: biochemical and linkage studies of the iduronate-2-sulfatase gene defects in MPS II patients and carriers. Clin Chim Acta 2006;369:29-34. https://doi.org/10.1016/j.cca.2006.01.001
  26. Chuang CK, Lin HY, Chiang CC, Chan MJ, Wang LY, Tu RY, et al. (2017) The current status of mucopolysaccharidosis I and II newborn screening, and the confirmation in Taiwan. (Free paper [poster]). The 69th American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo. San Diego, USA.
  27. Lin HY, Chuang CK, Chen MR, Lin SM, Hung CL, Chang CY, et al. Effects of enzyme replacement therapy on cardiac structure and function in patients with mucopolysaccharidoses I, II, IVA and VI. Mol Genet Metab 2016;117:431-7. https://doi.org/10.1016/j.ymgme.2016.02.003
  28. Lin HY, Chuang CK, Wang CH, Chien YH, Wang YM, Tsai FJ, et al. Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: a case series. Mol Genet Metab Rep 2016;7:63-9. https://doi.org/10.1016/j.ymgmr.2016.04.003
  29. Lin HY, Chen MR, Chuang CK, Chen CP, Lin DS, Chien YH, et al. Enzyme replacement therapy for mucopolysaccharidosis VI-experience in Taiwan. J Inherit Metab Dis 2010;33(Suppl 3):S421-7.
  30. Lin HY, Lin SP, Chuang CK, Chen MR, Chen BF, Wraith JE. Mucopolysaccharidosis under enzyme replacement therapy with laronidase-A mortality case with autopsy report. J Inherit Metab Dis 2005;28:1146-8. https://doi.org/10.1007/s10545-005-0211-x
  31. Beutler E. Gaucher's disease. N Engl J Med 1991;325:1354-60. https://doi.org/10.1056/NEJM199111073251906
  32. Lin WD, Wang CH, Che SY, Chiang CC, Kao SM, Tsai FJ. (2016) The Pilot Study of Newborn Screening and Gene Analysis of Gaucher Disease. (Free paper [oral]). The 228th scientific meeting of the Taiwan Pediatric Association. Taipei, Taiwan.
  33. Lin HY, Lin SP, Chuang CK, Wraith JE. Enzyme replacement therapy with imiglucerase in a Taiwanese child with type I Gaucher disease. J Chin Med Assoc 2006;69:228-32. https://doi.org/10.1016/S1726-4901(09)70224-2
  34. Gelb MH, Turecek F, Scott CR, Chamoles NA. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis 2006;29:397-404. https://doi.org/10.1007/s10545-006-0265-4
  35. Liao HC, Chiang CC, Niu DM, Wang CH, Kao SM, Tsai FJ, et al. Detecting multiple lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in Taiwan. Clin Chim Acta 2014;431:80-6. https://doi.org/10.1016/j.cca.2014.01.030
  36. Liao HC, Chan MJ, Yang CF, Chiang CC, Niu DM, Huang CK, et al. Mass spectrometry but not fluorometry distinguishes affected and pseudodeficiency patients in newborn screening for Pompe disease. Clin Chem 2017 Apr 27.
  37. Liu HC, Lin HY, Yang CF, Liao HC, Hsu TR, Lo CW, et al. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A). Orphanet J Rare Dis 2014;9:111. https://doi.org/10.1186/s13023-014-0111-y
  38. Liao HC, Huang YH, Chen YJ, Kao SM, Lin HY, Huang CK, et al. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A). Clin Chim Acta 2013;426:114-20. https://doi.org/10.1016/j.cca.2013.09.008
  39. Chien YH, Goldstein JL, Hwu WL, Smith PB, Lee NC, Chiang SC, et al. Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening. JIMD Rep 2015;19:67-73.

Cited by

  1. Molecular Analysis of Vietnamese Patients with Mucopolysaccharidosis Type I vol.11, pp.11, 2017, https://doi.org/10.3390/life11111162